A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials

Medicine & Life Sciences

• Oncolytic Virotherapy 100%
• Clinical Trials 42%
• Safety 37%
• Viruses 21%
• Chills 20%
• United States Food and Drug Administration 16%
• Nausea 14%
• Fatigue 13%
• Risk Assessment 13%
• Pharmaceutical Preparations 13%
• Fever 12%
• Neoplasms 10%
• Databases 9%
• Therapeutics 7%
• Infections 7%
• Genes 6%

Social Sciences

• adverse events 87%
• Clinical Trials 68%
• cancer 29%
• drug 21%
• clinical use 21%
• fatigue 17%
• risk assessment 15%